Table 3.

Responses at week 12.

A. Non-CNS responses at week 12
Response type	HER2− (n = 20) RECIST 1.1	HER2− (n = 20) irRC	HER2+ (n = 6) RECIST 1.1	HER2+ (n = 6) irRC
DCR	2 (10%)	2 (10%)	2 (33%)	1 (17%)
CR	0 (0%)	0 (0%)	0 (0%)	0 (0%)
PR	0 (0%)	0 (0%)	1 (17%)	1 (17%)
SD	2 (10%)	2 (10%)	1 (17%)	0 (0%)
PD	9 (45%)	9 (45%)	2 (33%)	3 (50%)
Not evaluablea	9 (45%)	9 (45%)	2 (33%)	2 (33%)

B. CNS responses at week 12
Response type	HER2− (n = 20) RANO-BM	HER2+ (n = 6) RANO-BM
DCR	9 (45%)	4 (67%)
CR	1 (5%)	1 (17%)
PR	2 (10%)	1 (17%)
SD	6 (30%)	2 (33%)
PD	2 (10%)	0 (0%)
Not evaluablea	9 (45%)	2 (33%)

CNS central nervous system, HER human epidermal growth factor receptor, RECIST response evaluation criteria in solid tumors, irRC immune-related response criteria, DCR disease control rate, CR complete response, PR partial response, SD stable disease, PD progressive disease, RANO-BM response assessment in neuro-oncology brain metastases.

^aDue to discontinuation or death prior to evaluation at 12 weeks.